Navidea Biopharmaceuticals Inc NAVB:NYSE American

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 12:24 PM EST
2.12quote price arrow down-0.05 (-2.30%)
Volume
209,327
52 week range
0.63 - 5.36

...

Loading . . .

KEY STATS

  • Open2.01
  • Day High2.18
  • Day Low2.01
  • Prev Close2.17
  • 52 Week High5.36
  • 52 Week High Date07/21/20
  • 52 Week Low0.63
  • 52 Week Low Date04/16/20
  • Market Cap56.58M
  • Shares Out26.69M
  • 10 Day Average Volume0.30M
  • Dividend-
  • Dividend Yield-
  • Beta1.91
  • 1 Year % Change99.52

RATIOS/PROFITABILITY

  • EPS (TTM)-0.52
  • P/E (TTM)-4.10
  • Fwd P/E (NTM)-17.67
  • EBITDA (MRQ)-8.635M
  • ROE (MRQ)-16,858.73%
  • Revenue (MRQ)820,000.00
  • Gross Margin (MRQ)99.86%
  • Net Margin (MRQ)-1,309.16%
  • Debt To Equity (MRQ)215.45%

EVENTS

  • Earnings Date03/15/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Navidea Biopharmaceuticals Inc News

There is no recent news for this security.

Latest NAVB News From Our Partners

QUOTE FINDER

Profile

MORE
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company...
Y. Michael Rice
Chairman
Jed Latkin
Chief Executive Officer
Address
4995 Bradenton Ave Ste 240
Dublin, OH
43017-3552
United States